Last updated: August 1, 2026
Dermatop is a prescription topical corticosteroid containing prednicarbate 0.1%. Its FDA-approved uses are short-term treatment of mild-to-moderate atopic dermatitis and relief of corticosteroid-responsive inflammatory dermatoses. The product is commercially mature, faces generic competition, has no meaningful current clinical-development program, and has limited remaining exclusivity value. Market growth is likely to track the broader topical corticosteroid market rather than new Dermatop-specific indications.
What is Dermatop and what is prednicarbate used for?
Dermatop contains prednicarbate, a synthetic nonhalogenated topical corticosteroid. U.S. dosage forms have included cream, ointment and emollient cream products at a 0.1% strength.
| Attribute |
Dermatop |
| Active ingredient |
Prednicarbate |
| Strength |
0.1% |
| Therapeutic class |
Topical corticosteroid |
| FDA route |
Topical |
| Main indication |
Mild-to-moderate atopic dermatitis |
| Prescription status |
Prescription drug |
| Product type |
Small-molecule dermatology drug |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Main competitors |
Generic prednicarbate and other topical corticosteroids |
| Original commercial category |
Branded prescription dermatology |
Prednicarbate is generally classified as a medium-potency topical corticosteroid, although potency classifications can vary by formulation, test method and jurisdiction. The product’s commercial value depends on formulation, vehicle, tolerability, prescriber familiarity and payer reimbursement rather than on active-ingredient exclusivity.
What is the FDA regulatory status of Dermatop?
Dermatop is an established FDA-approved prescription product. The product is not a new molecular entity and does not have the regulatory profile of a recently approved dermatology therapy.
The FDA labeling emphasizes short-term use, avoidance of prolonged treatment without medical supervision, and the risks associated with topical corticosteroid exposure. Label warnings include local adverse reactions, systemic absorption, hypothalamic-pituitary-adrenal-axis effects in high-risk situations, and pediatric precautions.[1]
Dermatop does not have an FDA biologics license application, and no biosimilar regulatory pathway applies. Generic prednicarbate products can generally enter through an abbreviated new drug application, subject to FDA requirements for pharmaceutical equivalence, bioequivalence or other applicable product-specific standards.
What formulations are protected by Dermatop?
The historical Dermatop franchise included topical vehicles designed to affect skin feel, spreadability, hydration and patient adherence. Formulation differentiation has included:
- Cream
- Ointment
- Emollient cream
- Topical preparations containing 0.1% prednicarbate
Vehicle-specific differentiation may influence substitution and prescribing, but it does not necessarily create durable commercial exclusivity. Generic applicants can target individual dosage forms separately, and FDA approval of one generic formulation does not automatically establish equivalence for every other vehicle.
Are there active Dermatop clinical trials?
No substantial current clinical-development program for branded Dermatop is evident in the major public trial registries. Prednicarbate has been studied historically in atopic dermatitis and other inflammatory skin conditions, but those studies are generally mature and do not indicate an active late-stage innovation program.[2]
What did earlier prednicarbate trials evaluate?
Historical clinical work focused on:
- Efficacy in atopic dermatitis
- Reduction of erythema, pruritus and inflammatory lesions
- Comparisons with other topical corticosteroids
- Local tolerability and skin atrophy
- Pediatric and adult use
- Cream, ointment and emollient vehicles
The clinical-development profile is consistent with an established topical corticosteroid. There is no clear public evidence of a current Phase 2 or Phase 3 program intended to expand Dermatop into a new indication, new mechanism or novel delivery system.
How does Dermatop compare with newer atopic dermatitis drugs?
| Drug or class |
Mechanism |
Typical commercial position |
Development status |
| Dermatop/prednicarbate |
Topical corticosteroid |
Established, low-cost anti-inflammatory |
Mature |
| Hydrocortisone and other corticosteroids |
Corticosteroid |
First-line and broad generic use |
Mature |
| Tacrolimus ointment |
Calcineurin inhibitor |
Steroid-sparing therapy |
Mature |
| Pimecrolimus cream |
Calcineurin inhibitor |
Steroid-sparing therapy |
Mature |
| Crisaborole |
PDE-4 inhibitor |
Nonsteroidal topical option |
Commercial |
| Ruxolitinib cream |
JAK inhibitor |
Newer nonsteroidal topical therapy |
Commercial, higher-value segment |
| Topical roflumilast |
PDE-4 inhibitor |
Newer nonsteroidal dermatology treatment |
Commercial |
Dermatop retains a role where clinicians want an established topical corticosteroid with a nonhalogenated prednicarbate active ingredient. It competes against a wide range of low-cost generic steroids and newer nonsteroidal products with differentiated safety or chronic-use positioning.
When does Dermatop lose exclusivity?
Dermatop has already lost practical market exclusivity in the United States. The product is an old small-molecule topical drug, and generic prednicarbate products are available or have been marketed in relevant dosage forms.
The original composition, formulation and use patents associated with an early prednicarbate product would have expired long before the current commercial period. Any remaining patent rights would need to be assessed by dosage form, jurisdiction and specific product listing. They would not restore broad active-ingredient exclusivity for prednicarbate.
What is the Orange Book status of Dermatop?
The Orange Book is relevant to approved U.S. drug products and listed patents. For an older topical corticosteroid such as Dermatop, the commercial question is whether any currently listed, unexpired patent blocks an ANDA applicant for a specific dosage form.
The practical status is:
| Orange Book issue |
Dermatop assessment |
| Active ingredient exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Not a current commercial barrier |
| Current branded exclusivity |
No meaningful broad exclusivity |
| Generic pathway |
ANDA pathway |
| Patent risk |
Product-specific and formulation-specific |
| Biosimilar risk |
Not applicable |
Patent status should be verified against the current FDA Orange Book patent and exclusivity listings for each referenced Dermatop product and dosage form.[3]
Are there Paragraph IV challenges to Dermatop?
Paragraph IV litigation is not a central current risk for Dermatop because generic prednicarbate competition already exists and the original exclusivity period has ended. A new Paragraph IV dispute would be more likely to concern a specific later-listed formulation patent than the prednicarbate molecule itself.
For an ANDA applicant, potential certification issues could involve:
- A listed formulation patent
- A vehicle-specific patent
- A method-of-use patent
- A patent associated with a particular strength or dosage form
No major, commercially material current Paragraph IV litigation involving the core Dermatop franchise is widely identified in the public record. The absence of a prominent dispute is consistent with the product’s age and genericized market structure.
What patent litigation and settlement agreements affect Dermatop?
No major current patent-litigation campaign appears to control U.S. access to prednicarbate products. The relevant historical patent estate is likely exhausted for core active-ingredient protection.
Settlement agreements can affect generic launch timing when a branded product retains enforceable formulation or use patents. That dynamic is more important for newer dermatology products than for Dermatop. Any agreement involving a specific prednicarbate manufacturer would require review of the court docket, FDA listing data and the relevant patent family before being treated as a market-wide restriction.
How strong is the Dermatop patent estate?
The current patent estate is weak from a commercial-exclusivity perspective.
| Patent-estate factor |
Assessment |
| Molecule protection |
Expired |
| Original product protection |
Expired or commercially exhausted |
| Formulation protection |
Limited, if any rights remain |
| Method-of-use protection |
Limited practical value |
| Manufacturing protection |
Potentially relevant to a supplier, not a broad market barrier |
| Generic substitution risk |
High |
| Ability to support premium pricing |
Low |
| Litigation leverage |
Low |
| Regulatory switching cost |
Moderate for formulation-specific products |
Manufacturing know-how may still matter operationally. Control of raw-material specifications, impurity profiles, topical uniformity, particle size, microbiological quality and stability can affect product approval and supply reliability. These factors are barriers to execution, not substitutes for expired patent exclusivity.
What is the Dermatop market outlook?
Dermatop is likely to remain a small, mature prescription dermatology brand or branded-generic product. Its market is structurally exposed to generic substitution, formulary pressure and price competition.
Market drivers
Demand is supported by:
- Continued prevalence of atopic dermatitis
- Recurrent use of topical anti-inflammatory treatment
- Physician familiarity with corticosteroids
- Low treatment cost relative to advanced biologic and targeted therapies
- Use across adult and pediatric dermatology
Market constraints
Growth is limited by:
- Generic prednicarbate competition
- Broad availability of alternative topical corticosteroids
- Payer preference for low-cost products
- Concerns about prolonged corticosteroid exposure
- Migration of some patients to nonsteroidal therapies
- Limited differentiation in the active ingredient
Dermatop five-year projection
A Dermatop-specific public revenue forecast is not available in the primary FDA or clinical-trial sources. A directional scenario is more appropriate than a point estimate.
| Period |
Expected market condition |
Revenue direction |
| Near term |
Stable demand, continued generic substitution |
Flat to declining |
| Mid term |
Mature topical corticosteroid use, pricing pressure |
Low-single-digit annual decline likely |
| Longer term |
Persistent clinical use but reduced branded share |
Decline in branded value; stable category demand |
The broader topical corticosteroid category can remain resilient even while Dermatop-specific revenue declines. Volume may be stable because atopic dermatitis remains prevalent, but unit economics are pressured by generic competition and payer substitution.
Which companies challenge Dermatop commercially?
Dermatop competes with generic manufacturers of prednicarbate and with companies selling alternative topical corticosteroids. Competitive pressure comes from both direct and indirect substitutes.
Direct competitors include manufacturers of generic prednicarbate cream, ointment and related formulations. Indirect competitors include suppliers of:
- Hydrocortisone
- Desonide
- Fluocinolone acetonide
- Triamcinolone acetonide
- Mometasone furoate
- Betamethasone products
- Tacrolimus
- Pimecrolimus
- Crisaborole
- Ruxolitinib cream
- Roflumilast topical products
The most important commercial distinction is price versus steroid-sparing positioning. Dermatop competes effectively on established use and cost, while newer nonsteroidal products compete on chronic-use tolerability, mechanism and label positioning.
What generic entry risks exist for Dermatop?
Generic-entry risk is already realized rather than prospective. The principal risks are:
- Loss of branded prescription share.
- Reimbursement-driven substitution.
- Price erosion across common topical vehicles.
- Retail and specialty-pharmacy inventory substitution.
- Reduced physician incentive to prescribe the branded product.
- Formulation-level competition from multiple generic suppliers.
A new manufacturer could still face technical barriers involving topical bioequivalence, product characterization, stability and manufacturing consistency. Those requirements may slow approval or reduce the number of viable suppliers, but they do not create durable market exclusivity once generic products are established.
What licensing deals affect Dermatop?
No major current licensing transaction is central to the commercial outlook for Dermatop. The product is not associated with a visible modern platform deal, co-development alliance or strategic dermatology licensing program comparable to transactions involving biologics, JAK inhibitors or novel topical delivery technologies.
Any remaining commercial value would be concentrated in:
- Regional distribution rights
- Authorized generic arrangements
- Manufacturer supply agreements
- Private-label commercialization
- Formulation or vehicle know-how
Key takeaways
- Dermatop is a mature 0.1% prednicarbate topical corticosteroid.
- Its primary clinical role is treatment of corticosteroid-responsive inflammatory dermatoses, including mild-to-moderate atopic dermatitis.
- No significant current Dermatop-specific clinical-trial program is evident.
- Core molecule and product exclusivity have expired.
- Generic competition is the main commercial risk and is already established.
- Biosimilar risk does not apply because prednicarbate is a small molecule.
- Formulation and manufacturing barriers may remain, but they do not provide broad market exclusivity.
- Dermatop-specific revenue is likely to decline or remain flat, while the broader topical corticosteroid category remains clinically durable.
- Newer nonsteroidal agents represent the main innovation threat, while low-cost generic corticosteroids represent the main pricing threat.
Frequently asked questions
Is Dermatop still FDA approved?
Yes. Dermatop is an established FDA-approved prescription topical corticosteroid containing prednicarbate, subject to the applicable FDA labeling and product availability.
Is prednicarbate stronger than hydrocortisone?
Prednicarbate is generally positioned above low-potency hydrocortisone products, but comparative potency depends on formulation, concentration and testing method. Clinicians select treatment based on disease severity, body site, patient age and duration of use.
Is Dermatop a biologic or biosimilar?
No. Dermatop contains the small molecule prednicarbate. It is regulated as a conventional prescription drug, and biosimilar rules do not apply.
Can Dermatop be used for chronic atopic dermatitis?
Topical corticosteroids can be used intermittently for recurrent atopic dermatitis under medical supervision. Long-term continuous use may increase the risk of local and systemic adverse effects, particularly on thin skin or in children.[1]
Does Dermatop have a meaningful patent barrier against generic manufacturers?
No broad current patent barrier is apparent for the core prednicarbate product. Any residual risk would be specific to a listed formulation, dosage form, method of use or manufacturing process.
References
-
U.S. Food and Drug Administration. (n.d.). Dermatop (prednicarbate) cream prescribing information. FDA labeling database.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Prednicarbate clinical studies. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
